menu ☰
menu ˟

FDA advisory committee to consider CV safety of romosozumab

15 Jan 2019
The Bone, Reproductive and Urologic Drugs Advisory Committee of the FDA will meet Wednesday to vote on whether to recommend approval of a biologics license application for the monoclonal antibody romosozumab for the treatment of osteoporosis in patie...

Click here to view the full article which appeared in

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.